Wimmer Associates 1 LLC Sells 7,089 Shares of Gilead Sciences, Inc. (GILD)
Wimmer Associates 1 LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 61.1% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,510 shares of the biopharmaceutical company’s stock after selling 7,089 shares during the period. Wimmer Associates 1 LLC’s holdings in Gilead Sciences were worth $306,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. ANTIPODES PARTNERS Ltd increased its stake in shares of Gilead Sciences by 23.4% in the first quarter. ANTIPODES PARTNERS Ltd now owns 781,418 shares of the biopharmaceutical company’s stock valued at $55,629,000 after buying an additional 148,226 shares during the period. Kempner Capital Management Inc. increased its stake in shares of Gilead Sciences by 108.9% in the first quarter. Kempner Capital Management Inc. now owns 64,462 shares of the biopharmaceutical company’s stock valued at $4,378,000 after buying an additional 33,604 shares during the period. SOL Capital Management CO increased its stake in shares of Gilead Sciences by 36.4% in the first quarter. SOL Capital Management CO now owns 8,900 shares of the biopharmaceutical company’s stock valued at $604,000 after buying an additional 2,375 shares during the period. Laurel Grove Capital LLC increased its stake in Gilead Sciences by 4.5% in the first quarter. Laurel Grove Capital LLC now owns 16,350 shares of the biopharmaceutical company’s stock worth $1,110,000 after buying an additional 700 shares during the last quarter. Finally, E&G Advisors LP increased its stake in Gilead Sciences by 0.4% in the first quarter. E&G Advisors LP now owns 25,694 shares of the biopharmaceutical company’s stock worth $1,745,000 after buying an additional 99 shares during the last quarter. 74.04% of the stock is owned by institutional investors and hedge funds.
Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded up 5.48% during mid-day trading on Wednesday, hitting $79.89. 13,159,011 shares of the stock were exchanged. The stock has a market capitalization of $104.33 billion, a P/E ratio of 8.68 and a beta of 1.21. The stock’s 50 day moving average price is $72.97 and its 200-day moving average price is $68.86. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.07. Gilead Sciences also was the recipient of unusually large options trading on Monday. Stock traders bought 19,878 put options on the company. This is an increase of 209% compared to the typical daily volume of 6,434 put options.
Gilead Sciences (NASDAQ:GILD) last released its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 EPS for the quarter, topping analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The firm had revenue of $7.14 billion for the quarter, compared to analysts’ expectations of $6.35 billion. During the same period in the prior year, the firm posted $3.08 earnings per share. The company’s quarterly revenue was down 8.2% on a year-over-year basis. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.73 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Thursday, September 28th. Stockholders of record on Friday, September 15th will be paid a $0.52 dividend. The ex-dividend date of this dividend is Thursday, September 14th. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.75%. Gilead Sciences’s dividend payout ratio is currently 22.58%.
COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.watchlistnews.com/wimmer-associates-1-llc-sells-7089-shares-of-gilead-sciences-inc-gild/1532158.html.
A number of equities research analysts have issued reports on GILD shares. Zacks Investment Research upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $76.00 target price for the company in a research report on Tuesday, May 2nd. Vetr lowered shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $74.34 price target on the stock. in a research note on Thursday, May 11th. Stifel Nicolaus restated a “buy” rating and set a $87.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Gabelli restated a “buy” rating and set a $85.00 price target on shares of Gilead Sciences in a research note on Wednesday, May 3rd. Finally, Deutsche Bank AG assumed coverage on shares of Gilead Sciences in a research note on Friday, June 23rd. They set a “buy” rating and a $79.00 price target on the stock. Eleven analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $80.83.
In other news, insider John C. Martin sold 73,333 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.86, for a total value of $5,563,041.38. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at $242,749,648.34. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Tuesday, August 1st. The stock was sold at an average price of $75.88, for a total value of $1,138,200.00. Following the completion of the sale, the executive vice president now directly owns 106,113 shares in the company, valued at $8,051,854.44. The disclosure for this sale can be found here. Over the last three months, insiders sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.